| Q37765549 | Amiodarone: review of pulmonary effects and toxicity |
| Q87061567 | Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study |
| Q36325381 | Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoidosis |
| Q34642424 | Database of bronchoalveolar lavage fluid proteins |
| Q36088248 | Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis |
| Q44117459 | Elevated serum KL-6 concentrations in patients with diabetes mellitus |
| Q79158643 | Increase of KL-6 in sera of uveitis patients with sarcoidosis |
| Q73820425 | KL-6, a human MUC1 mucin, is expressed early in premature lung |
| Q74621122 | Sarcoidosis: clinical manifestations, staging and therapy (Part II) |
| Q35549233 | Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis |
| Q37282892 | Serum ACE Level in Sarcoidosis Patients with Typical and Atypical HRCT Manifestation |
| Q43861082 | Serum KL-6 levels in pediatric patients: reference values for children and levels in pneumonia, asthma, and measles patients |
| Q24815010 | Serum biomarkers in interstitial lung diseases |
| Q43196827 | Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis |
| Q33816811 | Tubulointerstitial nephritis and uveitis (TINU) syndrome: epidemiology, diagnosis and management |
| Q34096375 | Tubulointerstitial nephritis with uveitis syndrome: A case report and review of literature |
| Q81140649 | Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis |